Fareon Announces Oral Presentation of First-in-Class Biophysics Treatment Results in Patients with Cognitive Impairment from Long COVID at the 2026 ISLC-PAIS Annual MeetingSAN FRANCISCO, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Fareon, a clinical-stage biophysics company pioneering novel therapies for brain disorders, brain injuries, and neurodevelopmental conditions, today announced that results of a clinical study evaluating its Fareon Restore™ biophysics platform in people with persistent, debilitating Long COVID brain fog will be presented at the International Society for Long COVID and Post-Acute Infection Syndromes (ISLC-PAIS) Annual Meeting, held August 26-29, 2026 in Amsterdam.
